Figure 4 | Cell Death & Disease

Figure 4

From: Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis

Figure 4

cAMP enhances APL progression in an NB4 orthotropic NSG model. (a) Survival of NB4-transplanted NOD-scid IL2rγnull mice (NSG) treated with vehicle (‘Ctrl’, n=5), dmPGE2/aminophylline (125 μg/kg/20 mg/kg, ‘cAMP’, n=6), daunorubicin (2.5 mg/kg, ‘DNR’, n=6) or daunorubicin+dmPGE2/aminophylline (‘DNR+cAMP’, n=6). The group that received cAMP agonists had significantly (P=0.003) shorter life span compared with the Ctrl group (average 32.8 against 28.8 days). DNR increased the average life span compared with the Ctrl group from 32.8 to 45.7 days, against 28.8 to 38.8 days for the DNR+cAMP group. (b) The weight of the NB4-transplanted NSG mice described in a relative to that (%) at the time of NB4 cell injection. The data show the average for all mice in each group

Back to article page